IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
RMDL: Classification of Parkinson's disease by nature-inspired Algorithm
Antidiabetic activity (In vitro alpha amylase inhibitory) of ethanol extract of Carissa carandas Linn. roots.
Six sigma: an embellished exploration in the field of pharmaceutical industry
The effect of Sida acuta on bacterial enzymes in azoxymethane-induced experimental colon cancer
Premature ageing in children: a rare genetic disorder called progeria.
Stress, Depression & Gut Microbiota: The Gut-Brain Axis Regulation
Zinc oxide nanoparticles and antibiotics mediated combinatorial approach to enhance antibacterial potential
Quality of life and associated factors among students in Jambi Province, Indonesia
Novel method for simultaneous determination of spiramycin and metronidazole in pharmaceutical dosage form by UV-visible absorption spectrophotometry
The Influence of Physicians Social Capital on Patients Satisfaction
1234
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
The Effectiveness of the Drug Uperio and Angiotensin-Converting Enzyme Inhibitors during Dilated Cardiomyopathy Complicated by Chronic Heart Failure

Author: ZALIM PANAGOV, ZUMURUD G. SAFAROVA, AL’BINA YU. SHERIEVA, ILONA R. GUDIEVA, ZAUR K.TSUKKIEV
Abstract: Introduction. One of the urgent problems in modern cardiology is the diagnosis of chronic heart failure (CHF) in the early stages of development and, therefore, improving the prognosis and quality of life of patients. The most significant reasons for the development of heart failure at a relatively young age include dilated cardiomyopathy (DCM), which manifests itself only with the development of heart failure. Clinical recommendations of recent decades dictate the need for the appointment of angiotensin-converting enzyme (ACE) inhibitors for the treatment of heart failure. In 2014, the results of a large randomized, double-blind clinical trial of PARADIGM-HF were published, during which the efficacy of standard therapy of heart failure with ACE inhibitors was compared with the new generation drug therapy Uperio. The purpose of this study is to compare the effect of the drug Uperio and ACE inhibitors on the course of DCM complicated by heart failure, according to the level of NT-proBNP and the value of hemodynamic parameters. Materials and methods. 32 patients with DCM complicated by heart failure were monitored in 2 groups: the main group (patients treated with Uperio) and the control group (patients treated with ACE inhibitors). Before the start of treatment and after its completion, an assessment of the clinical condition, an electrocardiographic and echocardiographic study, determination of the level of NT-proBNP in all patients were carried out. Research results and conclusions. Therapy with a new generation of Uperio leads to a more significant improvement in the clinical condition of patients with DCM than ACE inhibitors, reducing the intensity of shortness of breath by 78.1 and 65.6%, respectively. A more effective decrease in the level of NT-proBNP (by 47 and 22%, respectively) and an increase in the ejection fraction (by 10.2 and 6.3%, respectively) by the time of discharge in the group of patients taking Uperio were observed compared with the group of patients taking inhibitors ACE.
Keyword: cardiomyopathy, heart failure, ejection fraction, efficacy, NT-proBNP, therapy.
DOI: https://doi.org/10.31838/ijpr/2020.12.02.0065
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free